Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970739 | 0.82 | NCF1 (0.51) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL3970733 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL6804417 | 0.82 | ALDH1A1 (0.49) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL3962717 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EHTTRAB9AALDH1A1 | |
| SCHEMBL3964970 | 0.81 | CYP1A2 (0.51) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL3970289 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL4058393 | 0.76 | ADAM17 (0.60) | OPRL1 | |
| SCHEMBL10692338 | 0.74 | MAPT (0.46) | HTTRAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6788482 | 0.74 | CYP1A2 (0.56) | SMN1; SMN2KDM4EHTTRAB9ACYP1A2 | |
| SCHEMBL4438079 | 0.73 | CYP1A2 (0.53) | KDM4ERAB9ACYP1A2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | SMN1; SMN2 3011/4885KDM4E 2397/4885HTT 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.